- Molecular NameLisdexamfetamine
- Synonymlisdexamfetamine dimesylate; NRP104
- Weight263.385
- Drugbank_IDDB01255
- ACS_NO608137-32-2
- Show 2D model
- LogP (experiment)N/A
- LogP (predicted, AB/LogP v2.0)1.3
- pkaN/A
- LogD (pH=7, predicted)-2.18
- Solubility (experiment)792 mg/ml
- LogS (predicted, ACD/Labs)(ph=7)0.58
- LogSw (predicted, AB/LogsW2.0)4.17
- Sw (mg/ml) (predicted, ACD/Labs)9.74
- No.of HBond Donors5
- No.of HBond Acceptors4
- No.of Rotatable Bonds8
- TPSA81.14
- StatusFDA approved
- AdministrationN/A
- PharmacologyA psychoactive drug and stimulant prodrug of the phenethylamine and amphetamine chemical classes.
- Absorption_valueN/A
- Absorption (description)N/A
- Caco_2N/A
- Bioavailability5.0
- Protein bindingN/A
- Volume of distribution (VD)N/A
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmAfter oral administration, lisdexamfetamine dimesylate is rapidly absorbed from the gastrointestinal tract and converted to dextroamphetamine, which is responsible for the drug's activity.
- Half life< 1 h (prodrug molecule)
- ExcretionRenal: ~2%
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityAdverse events associated with discontinuation of treatment include ventricular hypertrophy, tic, vomiting, psychomotor hyperactivity, insomnia, and rash. Adverse events that occured in at least 5% of patients and at a rate twice that of the placebo group include upper abdominal pain, decreased appetite, dizziness, dry mouth, irritability, insomnia, nausea, vomiting, and decreased weight.
- LD50 (rat)N/A
- LD50 (mouse)N/A